YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Biocon added 1.36% to Rs 325.25 after the company announced that its subsidiary, Biocon Biologics (BBL), has launched YESINTEK (ustekinumab-kfce) in the United States.

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The Sensex closed marginally higher on Tuesday, while the Nifty ended flat, as gains in heavyweight financial and auto stocks ...

AAM said the law sets up a process under which a drug would have price controls applied before a generic or biosimilar even ...